Lobe Sciences Ltd. (CNSX:LOBE) signed a share purchase agreement to acquire Altemia and Company, LLC from Sancilio, LLC, PBHC1, LLC and Bruce Crawford for CAD 3.8 million on April 14, 2023. As per the terms of the transaction, Altemia shareholders will receive total consideration of CAD 3.8 million through the issuance on a pro-rata basis of an aggregate of 76 million common shares of Lobe (each a "Lobe Share") at a deemed issue price of CAD 0.05 per Lobe Share. Lobe will pay a tiered royalty of up to 10% on annual net sales of CAD 125 million or more and issue 3,000,000 warrants upon the first achievement of CAD 20 million in annual sales. The transaction also provides a 5% payment on the net sales revenue received for the sale of a Pediatric Priority Review Voucher for the approval of our SCD prescription drug for the Pediatric Orphan indication. The Transaction will be completed pursuant to exemptions from the prospectus and registration requirements under applicable securities laws.

Lobe Sciences Ltd. (CNSX:LOBE) completed the acquisition of Altemia and Company, LLC from Sancilio, LLC, PBHC1, LLC and Bruce Crawford for CAD 3.8 million.on April 17, 2023.